CenCal Health spent the last two years working on a system implementation project to replace our current system, and it appeared to have a great deal of potential. CenCal Health’s mission is to strive for excellence, and the product we had been working with did not meet our critical needs to ensure excellence for our providers and our members. After full deliberation, as an organization we decided that we deserve better and therefore we are terminating the adoption of our current system conversion plan. We will, however, continue to improve our CenCal Health Provider Portal. We’re confident that this is the right decision and don’t want to settle to be simply adequate, but exceptional! As we continue to refine our systems and business practices, we will continue to communicate these refinements and improvements with our valuable provider community.

Robert S. Freeman
CenCal Health, Chief Executive Officer

IN THIS ISSUE:
- CenCal Health System Conversion – Message from our CEO
- Skin Cancer Awareness
- CenCal Health Ranked #1 Place to Work
- Welcome to our Newest Medical Director
- Do You Suspect Fraud?
- Pharmacy Update Insert

CenCal Health System Conversion – Message from our CEO

May is Skin Cancer Awareness Month, which is a great time to remind your patients about ways to prevent skin cancer like avoiding Ultraviolet (UV) rays. UV rays from the sun and other sources like tanning beds are the primary cause of skin cancer, the most common cancer in the United States. During the summer months, it is key to promote the importance of sun safety to prevent skin cancer. The Friday before Memorial Day, May 24th, is designated as “Don't Fry Day,” a day to encourage everyone to take steps to protect their skin before summer officially kicks off!

For more information about “Don't Fry Day” and sun safety, please reference https://www.cancer.org/latest-news/special-coverage/dont-fry-day.html

Help Your Patients be Skin Cancer Aware

CenCal Health is pleased to share that it was recently ranked #1 “Central Coast Best Places to Work” in the Pacific Coast Business Times, a publication widely distributed in the Tri-Counties. CenCal Health staff voluntarily participated in a
Welcome to CenCal Health’s Newest Medical Director

Please welcome Pediatrics specialist Dr. Patricia Auchard, also known as “Dr. Patty,” to our organization as CenCal Health’s newest Medical Director. She will be working directly with Dr. Takashi Michael Wada, MD, MPH, CenCal Health’s Chief Medical Officer, on expanded benefits for behavioral health treatment, trauma and developmental screening as well as palliative care for the pediatric population, among other areas of focus.

Patricia Auchard, MD, obtained her bachelor’s degree at Harvard, and went on to complete her medical degree at UCLA. She completed her specialty in Pediatrics at Children’s Hospital in Los Angeles. Dr. Auchard is deeply involved and committed to health advocacy and education, especially with vulnerable populations. She has previously served on the California Breastfeeding Coalition, both as a member as well as Chairperson.

In addition, she is focused on inter-agency collaboration, especially identifying gaps and removing barriers to care for children ages 0-21 with special health care needs. Prior to arriving at CenCal Health, she worked as a Medical Director at the Gold Coast Health Plan in Ventura County, and held the position of the Medical Director of Children’s Medical Services, and Maternal, Child, and Adolescent Health for Ventura County Public Health.

“This CenCal Health has given me the opportunity to serve the Santa Barbara community and I am looking forward to learning about the San Luis Obispo community”, said Dr. Auchard.

Auchard was born in California and is bilingual and bi-cultural. Her professional special interests include helping children with developmental delay and/or special medical needs, individuals with developmental disabilities, and mental health and wellness.

Do You Suspect Fraud? Reporting is Everybody’s Business

CenCal Health believes in continually improving the healthcare delivery system and part of this is through detecting, correcting and preventing fraud, waste and abuse. You can help stop fraud, waste and abuse by reporting your concerns to CenCal Health anytime you feel any of these may be occurring.

**How To Report:**
- Call our toll free 24-hour hotline at (866) 775-3944, or
- Mail a completed Fraud, Waste and Abuse form located at www.cencalhealth.org/providers/suspect-fraud/

When reporting fraud, waste or abuse, please provide as much of the following information as possible:
- Name of person(s), facility, vendor, etc., suspected of committing fraud, waste or abuse.
- Identifying information such as: Provider/Member name, address or telephone number.
- Description and details of the suspected fraud, waste or abuse: who, what, where, when, date and time of incident or incidents.
- Any documentation you may have that is related to the situation.
- Your name and telephone if you would like to be contacted to validate information.
- You can remain anonymous.

CentCal Health Ranked #1 (continued from front page)

survey that allowed staff to answer multiple questions about their opinions of where they work. This is an exciting recognition for the organization that recently celebrated its 35th year in Santa Barbara County.

“As an employer, the organization’s greatest assets are its 250-some staff members”, said Karyn Fish, director of human resources. “The average employee tenure is a little more than seven years, and nearly a third of our employees have worked here for over 10 years.” Please read about it here: https://www.pacbiztimes.com/cencal-bptw2019/
Pharmacy Updates

Erythropoiesis-Stimulating-Agents (ESA) & Granulocyte Colony-Stimulating Factors (C-GSFs) Preferred Biosimilar Products

Effective June 1, 2019, Retacrit® (epoetin alfa-epbx) will be the preferred erythropoiesis-stimulating agent (ESA) on the CenCal Health Formulary. Epogen® and Procrit® will be removed from the CenCal Health formulary and will require a prior authorization indicating a trial/failure of the preferred ESA product.

Effective June 1, 2019, Zarxio® (filgrastim-sndz), Nivestym® (filgrastim-aafi), Fulphila® (pegfilgrastim-jmdb) and Udenyca® (pegfilgrastim-cbqv) will be the preferred Granulocyte Colony-Stimulating Factors (C-GSFs) on the CenCal Health Formulary. Neupogen® and Neulasta® will be removed from the CenCal Health formulary and will require a prior authorization indicating a trial/failure of the preferred C-GSF product.

Biosimilar Facts:
- Biosimilars are biologic medicines that are highly similar to their reference biologic, demonstrating no clinically meaningful differences in safety, purity, and potency compared to that of the reference product.
- All Biosimilar Products have been approved by the FDA.
- Biosimilars are not interchangeable with the reference products and will require a new prescription from the prescriber.

For additional information, please visit: https://www.cencalhealth.org/providers/pharmacy/

Please contact CenCal Health Pharmacy Department with questions at (805) 562-1080.